Che-Kai Tsao, MD is an Assistant Professor of Medicine, Hematology and Medical Oncology at the Tisch Cancer Institute, Mount Sinai Medical Center.
Dr. Tsao's primary research interest is the development of novel therapies in the treatment of genitourinary cancers, including prostate, bladder, and kidney malignancies.
Hematology
Medical Oncology
American Board of Internal Medicine
MD, SUNY Downstate Medical Center
Residency, Internal Medicine
Long Island Jewish Medical Center
Fellowship, Hematology/Oncology
Mount Sinai Hospital
Chinese (Mandarin), Chinese (Other), English
2012
GU Cancers Merit Award
American Society of Clinical Oncology
2012
Merit Award
American Society of Clinical Oncology
2012
Physician of the Year, Fellow Award
Mount Sinai Hospital
2011
Oncology Trainee Travel Award
American Society of Clinical Oncology
2011
Workshop on Methods in Clinical Cancer Research
ASCO/AACR
Genitourinary Cancers
Prostate Cancer, Kidney Cancer, Bladder Cancer, Testicular Cancer, and Adrenal Cancer.
A Phase I/II Study of Varlilumab (CDX-1127) in Combination with Sunitinib in Patients with Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to see whether varlilumab (study drug), when given in combination with sunitinib, an approved treatment for patients with advanced renal cell carcinaoma, is well tolerated. Additionally, researchers would like to know whether the combination of ...
Tsao CK, Galsky MD, Oh WK. Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. European urology 2014 Jan;.
Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Dec; 30(35).
Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute 2012 Dec; 104(23).
Tsao CK, Oh WK. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nature reviews. Clinical oncology 2012 Nov; 9(11).
Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012 Jun;.
Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Current opinion in urology 2012 May; 22(3).
Tsao C, Galsky MD, Small AC, Yee T, Oh WK. Targeting the Androgen Receptor Signaling Axis in Castration Resistant Prostate Cancer. British Journal of Urology-International;.
Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clinical genitourinary cancer 2012 Mar; 10(1).
Tsao CK, Oh WK. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian journal of andrology 2011 Mar; 13(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Tsao during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.